Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104


Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression.

Nugent AC, Carlson PJ, Bain EE, Eckelman W, Herscovitch P, Manji H, Zarate CA Jr, Drevets WC.

J Psychopharmacol. 2013 Oct;27(10):894-902. doi: 10.1177/0269881113499204.


Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression.

Nugent AC, Bain EE, Carlson PJ, Neumeister A, Bonne O, Carson RE, Eckelman W, Herscovitch P, Zarate CA Jr, Charney DS, Drevets WC.

Eur Neuropsychopharmacol. 2013 Aug;23(8):822-9. doi: 10.1016/j.euroneuro.2012.11.005.


Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression.

Sullivan GM, Ogden RT, Oquendo MA, Kumar JS, Simpson N, Huang YY, Mann JJ, Parsey RV.

Biol Psychiatry. 2009 Aug 1;66(3):223-30. doi: 10.1016/j.biopsych.2009.01.028.


Regional cerebral glucose metabolic abnormalities in bipolar II depression.

Mah L, Zarate CA Jr, Singh J, Duan YF, Luckenbaugh DA, Manji HK, Drevets WC.

Biol Psychiatry. 2007 Mar 15;61(6):765-75.


Higher pretreatment 5-HT1A receptor binding potential in bipolar disorder depression is associated with treatment remission: a naturalistic treatment pilot PET study.

Lan MJ, Hesselgrave N, Ciarleglio A, Ogden RT, Sullivan GM, Mann JJ, Parsey RV.

Synapse. 2013 Nov;67(11):773-8. doi: 10.1002/syn.21684.


PET imaging of brain 5-HT1A receptors in rat in vivo with 18F-FCWAY and improvement by successful inhibition of radioligand defluorination with miconazole.

Tipre DN, Zoghbi SS, Liow JS, Green MV, Seidel J, Ichise M, Innis RB, Pike VW.

J Nucl Med. 2006 Feb;47(2):345-53.


Antiapoptotic action of lithium and valproate.

Bielecka AM, Obuchowicz E.

Pharmacol Rep. 2008 Nov-Dec;60(6):771-82. Review.


Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade.

Rapoport SI.

ACS Chem Neurosci. 2014 Jun 18;5(6):459-67. doi: 10.1021/cn500058v. Review.


Behavioral depression and positron emission tomography-determined serotonin 1A receptor binding potential in cynomolgus monkeys.

Shively CA, Friedman DP, Gage HD, Bounds MC, Brown-Proctor C, Blair JB, Henderson JA, Smith MA, Buchheimer N.

Arch Gen Psychiatry. 2006 Apr;63(4):396-403.


PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy.

Toczek MT, Carson RE, Lang L, Ma Y, Spanaki MV, Der MG, Fazilat S, Kopylev L, Herscovitch P, Eckelman WC, Theodore WH.

Neurology. 2003 Mar 11;60(5):749-56.


Serotonin-1A receptor imaging in recurrent depression: replication and literature review.

Drevets WC, Thase ME, Moses-Kolko EL, Price J, Frank E, Kupfer DJ, Mathis C.

Nucl Med Biol. 2007 Oct;34(7):865-77. Review.


[Mood stabilizers--past, present and future].

Sümegi A.

Neuropsychopharmacol Hung. 2008 Mar;10(1):31-42. Review. Hungarian.


First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors.

Hillmer AT, Wooten DW, Bajwa AK, Higgins AT, Lao PJ, Betthauser TJ, Barnhart TE, Rowley HA, Stone CK, Johnson SC, Mukherjee J, Christian BT.

J Nucl Med. 2014 Dec;55(12):1973-9. doi: 10.2967/jnumed.114.145151.


Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.

Cipriani A, Reid K, Young AH, Macritchie K, Geddes J.

Cochrane Database Syst Rev. 2013 Oct 17;(10):CD003196. doi: 10.1002/14651858.CD003196.pub2. Review.


18F-FCWAY and 18F-FDG PET in MRI-negative temporal lobe epilepsy.

Liew CJ, Lim YM, Bonwetsch R, Shamim S, Sato S, Reeves-Tyer P, Herscovitch P, Dustin I, Bagic A, Giovacchini G, Theodore WH.

Epilepsia. 2009 Feb;50(2):234-9. doi: 10.1111/j.1528-1167.2008.01789.x.


Disulfiram inhibits defluorination of (18)F-FCWAY, reduces bone radioactivity, and enhances visualization of radioligand binding to serotonin 5-HT1A receptors in human brain.

Ryu YH, Liow JS, Zoghbi S, Fujita M, Collins J, Tipre D, Sangare J, Hong J, Pike VW, Innis RB.

J Nucl Med. 2007 Jul;48(7):1154-61. Erratum in: J Nucl Med. 2008 Apr;49(4):596.


Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.

Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM.

Cochrane Database Syst Rev. 2001;(3):CD003196. Review. Update in: Cochrane Database Syst Rev. 2013;10:CD003196.


Synthesis and biologic evaluation of a novel serotonin 5-HT1A receptor radioligand, 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primate.

Saigal N, Pichika R, Easwaramoorthy B, Collins D, Christian BT, Shi B, Narayanan TK, Potkin SG, Mukherjee J.

J Nucl Med. 2006 Oct;47(10):1697-706.


Sodium butyrate and mood stabilizers block ouabain-induced hyperlocomotion and increase BDNF, NGF and GDNF levels in brain of Wistar rats.

Varela RB, Valvassori SS, Lopes-Borges J, Mariot E, Dal-Pont GC, Amboni RT, Bianchini G, Quevedo J.

J Psychiatr Res. 2015 Feb;61:114-21. doi: 10.1016/j.jpsychires.2014.11.003.


A positron emission tomography study of the effects of treatment with valproate on brain 5-HT2A receptors in acute mania.

Yatham LN, Liddle PF, Lam RW, Adam MJ, Solomons K, Chinnapalli M, Ruth TJ.

Bipolar Disord. 2005;7 Suppl 5:53-7.

Items per page

Supplemental Content

Support Center